Child Development, Preterm Birth
Conditions
Brief summary
The purpose of this study is to examine whether supplementation with certain polyunsaturated fatty acids can help the cognitive development of children born preterm.
Interventions
200 mg DHA+ 200 mg AA per day for 6 months
400 mg corn oil per day for 6 months
Sponsors
Study design
Eligibility
Inclusion criteria
1. Age 10-16 completed months (age corrected for prematurity) at baseline 2. Discontinued regular breastfeeding and formula feeding at the time of randomization 3. Gestational age \< 35 completed weeks at birth 4. English is primary language in home 5. Informed consent obtained and signed 6. Child admitted to any NCH managed NICU or children who have ever had a Neonatology Clinic follow up visit scheduled, regardless of attendance
Exclusion criteria
1. Feeding problems 2. Major malformation, metabolic, or digestive disorder that would preclude participation and/or optimal absorption of the supplement. 3. Weight \< 5th or \> 95th percentile for age, per WHO growth charts 4. Consume DHA supplement drops, chews, or powders or Pediasure, or fatty fish more than 2x per week 5. Plans to move out of the area within the next 6 months 6. Known corn allergy 7. Known soy allergy 8. Known fish allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Erythrocyte Fatty Acid Levels | Baseline to 180 days post-randomization | This outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc |
| Erythrocyte Fatty Acid Levels (Additional Data) | Baseline to 180 days post-randomization | This outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc |
| Enrollment and Trial Completion | Baseline to 180 days post-randomization | The number of children who enroll in the trial and the number of those children who return for study visits 2 and 3. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc. |
| Adherence | Baseline to 180 days post-randomization | The mean (average) percentage of packets consumed by the children assigned to the supplement or placebo. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| (Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form) | Baseline to 180 days post-randomization | Infant Behavior Questionnaire-Revised (IBQ-R; short form) was used to assess effortful control (12 items) and activity level (3 items). The IBQ-R measures early temperament-based inhibitory control,a key component of executive function as children mature. Scores range from 1 to 7, with higher scores indicating greater frequency of behaviors. IBQ-R scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the IBQ-R value at 180 days minus the IBQ-R value at baseline). |
| (Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III) | Baseline to 180 days post-randomization | Bayley Scales of Infant and Toddler Development, third edition, (Bayley-III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items,score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit. Bayley-III scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the Bayley-III value at 180 days minus the Bayley-III value at baseline). Secondary Outcome for 1st stage of project funded by Allen Foundation, Inc; Primary Outcome for 2nd stage of project funded by March of Dimes and Health Resources and Services Administration |
Other
| Measure | Time frame | Description |
|---|---|---|
| Long-term Efficacy in Improving Cognition | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) cognitive outcome. This will be evaluated based on standard scores from the cognitive section of the Developmental Profile - 3. The range in standard scores is 40-140 with higher scores represent better cognitive ability. |
| Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P). The BRIEF-P yields five clinical scales, each measuring a different aspect of executive function: inhibit, shift, emotional control, working memory, and plan/organize. The clinical scales merge to create four broad indices of executive function: inhibitory self-control, flexibility, emergent metacognition, and global executive composite. A t-score of 50 is equal to the population mean with scores below 50 indicating better executive function, and scores above 50 indicating worse executive function for each reported aspect. |
| Long-term Efficacy in Improving Executive Functions (CBCL) | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Attention Deficit/Hyperactivity Problems DSM oriented subscale and the Attention syndrome subscale of the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less behavioral problems, and scores above 50 indicating more behavioral problems. |
| Brief Infant Sleep Questionnaire (BISQ) | Baseline to 180 days post-randomization | The following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the BISQ value at 180 days minus the BISQ value at baseline). |
| Other Long-term Outcomes: Language | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Communicative Development Inventory (CDI). On this measure, caregivers selected the number of words from a list of 100 common words that their child used. Scores reflect the total number of words, from the list of 100, that the child used. |
| Other Long-term Outcomes: Number of Participants With Developmental Delay | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of developmental delay. |
| Other Long-term Outcomes: Number of Participants With Behavior Difficulties | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of behavioral difficulties. |
| Other Long-term Outcomes: Pervasive Developmental Problems | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Pervasive Developmental Problems DSM oriented scale on the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less problems and scores above 50 indicating more problems. |
| Body Composition | Baseline to 180 days post-randomization | Changes in body composition from baseline to 6 months post-randomization (weight, recumbent length, head circumference, mid-upper arm circumference, triceps and subscapular skinfolds). These measurements were converted to z scores for corrected age based on Child Growth Standards from the World Health Organization. The z-score indicates the number of standard deviations away from the mean. A z score of 0 is equal to the mean of a reference population (children the same age and sex). Values less than 0 indicate values lower than the reference population, while values greater than 0 indicate values higher than the reference population. |
| Brief Infant Toddler Social Emotional Assessment (BITSEA) | 180 days post-randomization | BITSEA measures socioemotional development in toddlerhood. Scores were summed to provide competence (range: 0-22) and problem (range: 0-62) scores, respectively. The problem scale is further divided into subscales: externalizing (6 items; range: 0-12), internalizing (8 items; range: 0-16), and dysregulation (8 items; range: 0-16). Additionally, 14 items comprise a red flag scale (range: 0-28). Eight items from the competence and nine items from the problem subscales are indicative of behaviors often seen in children with ASD. Each of the 17 ASD items was dichotomized to illustrate the presence (1) (i.e., competence items absent, problem items present) or absence (0) (i.e., competence items present, problem items absent) of each ASD behavior. Items were then summed to derive an ASD score (range: 0-17). Higher competence scores represent better functioning, whereas higher problem (including the problem subscales), red flag, and ASD scores were indicative of poorer functioning. |
| Pervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II) | 180 days post-randomization | The PDDST-II is a clinically derived, caregiver-completed screener to assist in differentiating an ASD diagnosis from other disorders in children with developmental concerns, including those born preterm. The PDDST-II comprised 14 yes/no items that indicate the presence (1) or absence (0) of developmental concerns. Items were summed (possible range: 0-14) and higher scores represented greater developmental concern. |
| Other Long-term Outcomes: Sleep (BISQ) | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Brief Infant Sleep Questionnaire (BISQ).The following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at post-intervention follow-up (approximately 8 months after the trial ended). The scores were calculated as a change between two time points (the BISQ value at post-intervention follow-up minus the BISQ value at baseline). |
| Other Long-term Outcomes: Sleep (CSHQ) | Long-term effect (approximately 8 months) after intervention completion | Long-term (26-32 months of age) outcomes. This will be evaluated using the total score on a subset of 13 items from the Children's Sleep Habits Questionnaire (CSHQ). The range in total score is 13-39. A higher score is indicative of more sleep problems. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Docosahexaenoic Acid + Arachidonic Acid Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
Docosahexaenoic Acid + Arachidonic Acid (DHA+AA): 200 mg DHA+ 200 mg AA per day for 6 months | 189 |
| Placebo Corn oil supplement
Placebo: 400 mg corn oil per day for 6 months | 188 |
| Total | 377 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Change in Medical Care | 1 | 0 |
| Overall Study | Lost to Follow-up | 14 | 16 |
| Overall Study | Withdrawal by Subject | 5 | 1 |
Baseline characteristics
| Characteristic | Docosahexaenoic Acid + Arachidonic Acid | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 15.7 Months | 15.7 Months | 15.6 Months |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants | 17 Participants | 10 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 182 Participants | 360 Participants | 178 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 52 Participants | 105 Participants | 53 Participants |
| Race (NIH/OMB) More than one race | 21 Participants | 33 Participants | 12 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 114 Participants | 236 Participants | 122 Participants |
| Region of Enrollment United States | 189 participants | 377 participants | 188 participants |
| Sex: Female, Male Female | 84 Participants | 182 Participants | 98 Participants |
| Sex: Female, Male Male | 105 Participants | 195 Participants | 90 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 189 | 0 / 188 |
| other Total, other adverse events | 127 / 189 | 129 / 188 |
| serious Total, serious adverse events | 0 / 189 | 0 / 188 |
Outcome results
Adherence
The mean (average) percentage of packets consumed by the children assigned to the supplement or placebo. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc
Time frame: Baseline to 180 days post-randomization
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Adherence | 80.6 average percentage of packets consumed | Standard Deviation 28 |
| Placebo | Adherence | 80.7 average percentage of packets consumed | Standard Deviation 25 |
Enrollment and Trial Completion
The number of children who enroll in the trial and the number of those children who return for study visits 2 and 3. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc.
Time frame: Baseline to 180 days post-randomization
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Enrollment and Trial Completion | Study Visit 2 Completion | 172 Participants |
| Docosahexaenoic Acid + Arachidonic Acid | Enrollment and Trial Completion | Study Visit 3 Completion | 166 Participants |
| Placebo | Enrollment and Trial Completion | Study Visit 2 Completion | 163 Participants |
| Placebo | Enrollment and Trial Completion | Study Visit 3 Completion | 168 Participants |
Erythrocyte Fatty Acid Levels
This outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc
Time frame: Baseline to 180 days post-randomization
Population: Rows titles are fatty acids with different C:D ratio where, C= Carbohydrate; D = Double bond; C:D is the ratio of the total amount of Carbon atoms of the fatty acid in relation to the number of double (unsaturated) bonds in it. Funding allotted for 205 children to be randomized to provide blood specimens but only 173 gave pre and post samples
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | Eicosapentaenoic acid (20:5n-3) | 0.0 nmol/mL | Standard Deviation 0.1 |
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | Linoleic acid (18:2n-6) | -2.1 nmol/mL | Standard Deviation 5.2 |
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | Docosapentaenoic acid (22:5n-3) | -0.1 nmol/mL | Standard Deviation 0.1 |
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | Total n-6 | 0.2 nmol/mL | Standard Deviation 6 |
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | Docosahexaenoic acid (22:6n-3) | 1.1 nmol/mL | Standard Deviation 1 |
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | α-linolenic acid (18:3n-3) | -0.1 nmol/mL | Standard Deviation 0.4 |
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | Total n-3 | 0.9 nmol/mL | Standard Deviation 1.1 |
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels | Arachidonic acid (20:4n-6) | 2.0 nmol/mL | Standard Deviation 2.6 |
| Placebo | Erythrocyte Fatty Acid Levels | Total n-3 | -0.2 nmol/mL | Standard Deviation 0.5 |
| Placebo | Erythrocyte Fatty Acid Levels | Linoleic acid (18:2n-6) | 0.6 nmol/mL | Standard Deviation 4.4 |
| Placebo | Erythrocyte Fatty Acid Levels | Arachidonic acid (20:4n-6) | -0.2 nmol/mL | Standard Deviation 1.1 |
| Placebo | Erythrocyte Fatty Acid Levels | α-linolenic acid (18:3n-3) | 0.0 nmol/mL | Standard Deviation 0.3 |
| Placebo | Erythrocyte Fatty Acid Levels | Eicosapentaenoic acid (20:5n-3) | -0.1 nmol/mL | Standard Deviation 0.2 |
| Placebo | Erythrocyte Fatty Acid Levels | Docosapentaenoic acid (22:5n-3) | 0.0 nmol/mL | Standard Deviation 0.1 |
| Placebo | Erythrocyte Fatty Acid Levels | Docosahexaenoic acid (22:6n-3) | -0.1 nmol/mL | Standard Deviation 0.2 |
| Placebo | Erythrocyte Fatty Acid Levels | Total n-6 | 0.4 nmol/mL | Standard Deviation 5 |
Erythrocyte Fatty Acid Levels (Additional Data)
This outcome measure involved an examination of change in plasma and RBC fatty acid concentrations from the first study visit to the final study visit. The changes were calculated as the fatty acid level at 180 days minus the fatty acid level at baseline. Primary Outcome for 1st stage of project funded by Allen Foundation, Inc
Time frame: Baseline to 180 days post-randomization
Population: Rows titles are fatty acids with different C:D ratio where, C= Carbohydrate; D = Double bond; C:D is the ratio of the total amount of Carbon atoms of the fatty acid in relation to the number of double (unsaturated) bonds in it. Funding allotted for 205 children to be randomized to provide blood specimens but only 173 gave pre and post samples
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Erythrocyte Fatty Acid Levels (Additional Data) | -3.2 ratio | Standard Deviation 3.9 |
| Placebo | Erythrocyte Fatty Acid Levels (Additional Data) | 1.6 ratio | Standard Deviation 2.8 |
(Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form)
Infant Behavior Questionnaire-Revised (IBQ-R; short form) was used to assess effortful control (12 items) and activity level (3 items). The IBQ-R measures early temperament-based inhibitory control,a key component of executive function as children mature. Scores range from 1 to 7, with higher scores indicating greater frequency of behaviors. IBQ-R scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the IBQ-R value at 180 days minus the IBQ-R value at baseline).
Time frame: Baseline to 180 days post-randomization
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | (Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form) | Activity Level | 0.6 units on a scale | Standard Deviation 1.5 |
| Docosahexaenoic Acid + Arachidonic Acid | (Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form) | Effortful Control | -0.7 units on a scale | Standard Deviation 0.8 |
| Placebo | (Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form) | Effortful Control | -0.5 units on a scale | Standard Deviation 0.8 |
| Placebo | (Behavior) Infant Behavior Questionnaire-Revised (IBQ-R; Short Form) | Activity Level | 0.5 units on a scale | Standard Deviation 1.5 |
(Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III)
Bayley Scales of Infant and Toddler Development, third edition, (Bayley-III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items,score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit. Bayley-III scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the Bayley-III value at 180 days minus the Bayley-III value at baseline). Secondary Outcome for 1st stage of project funded by Allen Foundation, Inc; Primary Outcome for 2nd stage of project funded by March of Dimes and Health Resources and Services Administration
Time frame: Baseline to 180 days post-randomization
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | (Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III) | Cognitive Composite | -2.6 units on a scale | Standard Deviation 13.3 |
| Docosahexaenoic Acid + Arachidonic Acid | (Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III) | Language Composite | -0.5 units on a scale | Standard Deviation 12 |
| Docosahexaenoic Acid + Arachidonic Acid | (Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III) | Motor Composite | -0.6 units on a scale | Standard Deviation 12.5 |
| Placebo | (Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III) | Cognitive Composite | -3.7 units on a scale | Standard Deviation 12.2 |
| Placebo | (Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III) | Language Composite | 0.2 units on a scale | Standard Deviation 12.6 |
| Placebo | (Development) Bayley Scales of Infant and Toddler Development, Third Edition(Bayley-III) | Motor Composite | -0.4 units on a scale | Standard Deviation 12.7 |
Body Composition
Changes in body composition from baseline to 6 months post-randomization (weight, recumbent length, head circumference, mid-upper arm circumference, triceps and subscapular skinfolds). These measurements were converted to z scores for corrected age based on Child Growth Standards from the World Health Organization. The z-score indicates the number of standard deviations away from the mean. A z score of 0 is equal to the mean of a reference population (children the same age and sex). Values less than 0 indicate values lower than the reference population, while values greater than 0 indicate values higher than the reference population.
Time frame: Baseline to 180 days post-randomization
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Body Composition | Recumbent Length | 0.1 z scores | Standard Deviation 0.9 |
| Docosahexaenoic Acid + Arachidonic Acid | Body Composition | Mid-Upper Arm Circumference | 0.0 z scores | Standard Deviation 0.8 |
| Docosahexaenoic Acid + Arachidonic Acid | Body Composition | Weight | 0.1 z scores | Standard Deviation 0.4 |
| Docosahexaenoic Acid + Arachidonic Acid | Body Composition | Triceps Skinfold | -0.0 z scores | Standard Deviation 0.7 |
| Docosahexaenoic Acid + Arachidonic Acid | Body Composition | Head Circumference | -0.0 z scores | Standard Deviation 0.6 |
| Docosahexaenoic Acid + Arachidonic Acid | Body Composition | Subscapular Skinfold | -0.2 z scores | Standard Deviation 0.8 |
| Placebo | Body Composition | Subscapular Skinfold | -0.2 z scores | Standard Deviation 0.9 |
| Placebo | Body Composition | Weight | 0.0 z scores | Standard Deviation 0.4 |
| Placebo | Body Composition | Recumbent Length | 0.2 z scores | Standard Deviation 0.9 |
| Placebo | Body Composition | Head Circumference | -0.1 z scores | Standard Deviation 0.5 |
| Placebo | Body Composition | Mid-Upper Arm Circumference | 0.1 z scores | Standard Deviation 0.7 |
| Placebo | Body Composition | Triceps Skinfold | -0.1 z scores | Standard Deviation 0.8 |
Brief Infant Sleep Questionnaire (BISQ)
The following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at study completion (180 days post randomization). The scores were calculated as a change between two time points (the BISQ value at 180 days minus the BISQ value at baseline).
Time frame: Baseline to 180 days post-randomization
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Sleep Questionnaire (BISQ) | Nocturnal Sleep Duration | 0.25 hours | Standard Deviation 1.61 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Sleep Questionnaire (BISQ) | Daytime Sleep Duration | -0.32 hours | Standard Deviation 1.15 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Sleep Questionnaire (BISQ) | Total Sleep Duration | -0.07 hours | Standard Deviation 2.22 |
| Placebo | Brief Infant Sleep Questionnaire (BISQ) | Nocturnal Sleep Duration | -0.16 hours | Standard Deviation 1.34 |
| Placebo | Brief Infant Sleep Questionnaire (BISQ) | Daytime Sleep Duration | -0.46 hours | Standard Deviation 1.25 |
| Placebo | Brief Infant Sleep Questionnaire (BISQ) | Total Sleep Duration | -0.57 hours | Standard Deviation 1.7 |
Brief Infant Toddler Social Emotional Assessment (BITSEA)
BITSEA measures socioemotional development in toddlerhood. Scores were summed to provide competence (range: 0-22) and problem (range: 0-62) scores, respectively. The problem scale is further divided into subscales: externalizing (6 items; range: 0-12), internalizing (8 items; range: 0-16), and dysregulation (8 items; range: 0-16). Additionally, 14 items comprise a red flag scale (range: 0-28). Eight items from the competence and nine items from the problem subscales are indicative of behaviors often seen in children with ASD. Each of the 17 ASD items was dichotomized to illustrate the presence (1) (i.e., competence items absent, problem items present) or absence (0) (i.e., competence items present, problem items absent) of each ASD behavior. Items were then summed to derive an ASD score (range: 0-17). Higher competence scores represent better functioning, whereas higher problem (including the problem subscales), red flag, and ASD scores were indicative of poorer functioning.
Time frame: 180 days post-randomization
Population: The number analyzed for the competence and ASD scales differs from the overall number analyzed due to missing data on these two scales.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Externalizing | 2.29 units on a scale | Standard Deviation 2.06 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Dysregulation | 3.25 units on a scale | Standard Deviation 2.57 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Problem | 9.81 units on a scale | Standard Deviation 6.01 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Red Flag | 2.93 units on a scale | Standard Deviation 2.48 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Internalizing | 2.04 units on a scale | Standard Deviation 1.58 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Toddler Social Emotional Assessment (BITSEA) | ASD | 4.11 units on a scale | Standard Deviation 2.29 |
| Docosahexaenoic Acid + Arachidonic Acid | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Competence | 16.50 units on a scale | Standard Deviation 3.09 |
| Placebo | Brief Infant Toddler Social Emotional Assessment (BITSEA) | ASD | 4.36 units on a scale | Standard Deviation 2.98 |
| Placebo | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Competence | 16.73 units on a scale | Standard Deviation 2.94 |
| Placebo | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Problem | 10.18 units on a scale | Standard Deviation 6.84 |
| Placebo | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Externalizing | 2.30 units on a scale | Standard Deviation 1.98 |
| Placebo | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Internalizing | 2.31 units on a scale | Standard Deviation 2.1 |
| Placebo | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Dysregulation | 3.29 units on a scale | Standard Deviation 2.59 |
| Placebo | Brief Infant Toddler Social Emotional Assessment (BITSEA) | Red Flag | 3.12 units on a scale | Standard Deviation 2.85 |
Long-term Efficacy in Improving Cognition
Long-term (26-32 months of age) cognitive outcome. This will be evaluated based on standard scores from the cognitive section of the Developmental Profile - 3. The range in standard scores is 40-140 with higher scores represent better cognitive ability.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Cognition | 103.36 units on a scale | Standard Deviation 19 |
| Placebo | Long-term Efficacy in Improving Cognition | 107.93 units on a scale | Standard Deviation 19.93 |
Long-term Efficacy in Improving Executive Functions (BRIEF-P)
Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P). The BRIEF-P yields five clinical scales, each measuring a different aspect of executive function: inhibit, shift, emotional control, working memory, and plan/organize. The clinical scales merge to create four broad indices of executive function: inhibitory self-control, flexibility, emergent metacognition, and global executive composite. A t-score of 50 is equal to the population mean with scores below 50 indicating better executive function, and scores above 50 indicating worse executive function for each reported aspect.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Shift | 47.08 units on a scale | Standard Deviation 8.89 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Inhibitory Self-control Index | 49.44 units on a scale | Standard Deviation 9.44 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Working Memory | 53.79 units on a scale | Standard Deviation 11.3 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Flexibility Index | 47.62 units on a scale | Standard Deviation 8.72 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Emotional Control | 48.55 units on a scale | Standard Deviation 8.2 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Emergent Metacognition Index | 52.17 units on a scale | Standard Deviation 11.27 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Plan/Organize | 49.66 units on a scale | Standard Deviation 10.58 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Global Executive Composite | 50.09 units on a scale | Standard Deviation 10.6 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Inhibit | 50.20 units on a scale | Standard Deviation 10.69 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Global Executive Composite | 52.67 units on a scale | Standard Deviation 12.51 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Inhibit | 51.91 units on a scale | Standard Deviation 10.57 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Shift | 49.16 units on a scale | Standard Deviation 9.92 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Emotional Control | 49.98 units on a scale | Standard Deviation 9.33 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Working Memory | 56.04 units on a scale | Standard Deviation 13.63 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Plan/Organize | 52.69 units on a scale | Standard Deviation 12.02 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Inhibitory Self-control Index | 51.13 units on a scale | Standard Deviation 10.23 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Flexibility Index | 49.60 units on a scale | Standard Deviation 9.88 |
| Placebo | Long-term Efficacy in Improving Executive Functions (BRIEF-P) | Emergent Metacognition Index | 55.01 units on a scale | Standard Deviation 13.76 |
Long-term Efficacy in Improving Executive Functions (CBCL)
Long-term (26-32 months of age) executive function outcomes. This will be evaluated using scores on the Attention Deficit/Hyperactivity Problems DSM oriented subscale and the Attention syndrome subscale of the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less behavioral problems, and scores above 50 indicating more behavioral problems.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (CBCL) | Attention Deficit/Hyperactivity Problems | 55.04 t-score | Standard Deviation 6.9 |
| Docosahexaenoic Acid + Arachidonic Acid | Long-term Efficacy in Improving Executive Functions (CBCL) | Attention Problems | 55.21 t-score | Standard Deviation 7.1 |
| Placebo | Long-term Efficacy in Improving Executive Functions (CBCL) | Attention Deficit/Hyperactivity Problems | 55.08 t-score | Standard Deviation 6.43 |
| Placebo | Long-term Efficacy in Improving Executive Functions (CBCL) | Attention Problems | 55.71 t-score | Standard Deviation 6.82 |
Other Long-term Outcomes: Language
Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Communicative Development Inventory (CDI). On this measure, caregivers selected the number of words from a list of 100 common words that their child used. Scores reflect the total number of words, from the list of 100, that the child used.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Language | 56.68 words | Standard Deviation 28.75 |
| Placebo | Other Long-term Outcomes: Language | 61.15 words | Standard Deviation 27.94 |
Other Long-term Outcomes: Number of Participants With Behavior Difficulties
Long-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of behavioral difficulties.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Number of Participants With Behavior Difficulties | 5 Participants |
| Placebo | Other Long-term Outcomes: Number of Participants With Behavior Difficulties | 1 Participants |
Other Long-term Outcomes: Number of Participants With Developmental Delay
Long-term (26-32 months of age) outcomes. This will be evaluated using caregiver reports/diagnoses of developmental delay.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Number of Participants With Developmental Delay | 30 Participants |
| Placebo | Other Long-term Outcomes: Number of Participants With Developmental Delay | 18 Participants |
Other Long-term Outcomes: Pervasive Developmental Problems
Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Pervasive Developmental Problems DSM oriented scale on the Child Behavior Checklist 1.5-5 (CBCL). A t-score of 50 is equal to the population mean with scores below 50 indicating less problems and scores above 50 indicating more problems.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Pervasive Developmental Problems | 53.76 t-score | Standard Deviation 6.12 |
| Placebo | Other Long-term Outcomes: Pervasive Developmental Problems | 55.54 t-score | Standard Deviation 7.78 |
Other Long-term Outcomes: Sleep (BISQ)
Long-term (26-32 months of age) outcomes. This will be evaluated using scores on the Brief Infant Sleep Questionnaire (BISQ).The following sleep characteristics were captured based on caregiver-report: nocturnal sleep duration (hours), daytime sleep duration (hours), total sleep duration within a 24-hour period (hours). Larger values represent more time spent in each type of sleep. BISQ scores were measured at baseline and then again at post-intervention follow-up (approximately 8 months after the trial ended). The scores were calculated as a change between two time points (the BISQ value at post-intervention follow-up minus the BISQ value at baseline).
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Sleep (BISQ) | Nocturnal Sleep Duration | -0.11 hours | Standard Deviation 1.68 |
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Sleep (BISQ) | Daytime Sleep Duration | -0.46 hours | Standard Deviation 1.3 |
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Sleep (BISQ) | Total Sleep Duration | -0.57 hours | Standard Deviation 2.2 |
| Placebo | Other Long-term Outcomes: Sleep (BISQ) | Nocturnal Sleep Duration | -0.38 hours | Standard Deviation 1.43 |
| Placebo | Other Long-term Outcomes: Sleep (BISQ) | Daytime Sleep Duration | -0.81 hours | Standard Deviation 1.41 |
| Placebo | Other Long-term Outcomes: Sleep (BISQ) | Total Sleep Duration | -1.17 hours | Standard Deviation 1.85 |
Other Long-term Outcomes: Sleep (CSHQ)
Long-term (26-32 months of age) outcomes. This will be evaluated using the total score on a subset of 13 items from the Children's Sleep Habits Questionnaire (CSHQ). The range in total score is 13-39. A higher score is indicative of more sleep problems.
Time frame: Long-term effect (approximately 8 months) after intervention completion
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Other Long-term Outcomes: Sleep (CSHQ) | 18.82 units on a scale | Standard Deviation 4.96 |
| Placebo | Other Long-term Outcomes: Sleep (CSHQ) | 19.57 units on a scale | Standard Deviation 5.4 |
Pervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II)
The PDDST-II is a clinically derived, caregiver-completed screener to assist in differentiating an ASD diagnosis from other disorders in children with developmental concerns, including those born preterm. The PDDST-II comprised 14 yes/no items that indicate the presence (1) or absence (0) of developmental concerns. Items were summed (possible range: 0-14) and higher scores represented greater developmental concern.
Time frame: 180 days post-randomization
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Docosahexaenoic Acid + Arachidonic Acid | Pervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II) | 2.91 units on a scale | Standard Deviation 2.35 |
| Placebo | Pervasive Developmental Disorders Screening Test - II, Stage 2 (PDDST-II) | 3.37 units on a scale | Standard Deviation 3.02 |